2seventy bio, Inc. (NASDAQ:TSVT) Shares Purchased by Venator Management LLC

Venator Management LLC boosted its position in shares of 2seventy bio, Inc. (NASDAQ:TSVT) by 49.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 485,000 shares of the company’s stock after acquiring an additional 160,000 shares during the period. 2seventy bio comprises 0.6% of Venator Management LLC’s investment portfolio, making the stock its 18th biggest holding. Venator Management LLC owned about 0.94% of 2seventy bio worth $1,867,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Nisa Investment Advisors LLC acquired a new position in shares of 2seventy bio during the second quarter worth $52,000. BBR Partners LLC lifted its holdings in 2seventy bio by 66.7% during the 2nd quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock worth $96,000 after buying an additional 10,000 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of 2seventy bio by 2,637.0% during the 1st quarter. Public Employees Retirement System of Ohio now owns 27,370 shares of the company’s stock worth $146,000 after acquiring an additional 26,370 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of 2seventy bio by 11.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 28,929 shares of the company’s stock valued at $155,000 after acquiring an additional 2,893 shares during the last quarter. Finally, Pale Fire Capital SE raised its position in shares of 2seventy bio by 67.5% during the 4th quarter. Pale Fire Capital SE now owns 40,688 shares of the company’s stock worth $174,000 after acquiring an additional 16,400 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

2seventy bio Trading Down 1.7 %

Shares of TSVT opened at $4.72 on Thursday. The company’s 50 day simple moving average is $4.55 and its 200-day simple moving average is $4.54. The firm has a market cap of $243.08 million, a PE ratio of -1.09 and a beta of 1.77. 2seventy bio, Inc. has a 12-month low of $1.53 and a 12-month high of $6.40.

2seventy bio (NASDAQ:TSVT) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $8.97 million for the quarter, compared to the consensus estimate of $11.43 million. 2seventy bio had a negative net margin of 354.16% and a negative return on equity of 66.01%. As a group, equities research analysts forecast that 2seventy bio, Inc. will post -0.79 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on TSVT shares. The Goldman Sachs Group downgraded 2seventy bio from a “neutral” rating to a “sell” rating and lowered their price target for the company from $5.00 to $2.00 in a report on Thursday, June 6th. Morgan Stanley reduced their price objective on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $5.00 target price on shares of 2seventy bio in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.00.

Insider Buying and Selling

In other 2seventy bio news, insider Jessica Snow sold 7,816 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $4.32, for a total transaction of $33,765.12. Following the completion of the sale, the insider now directly owns 156,330 shares of the company’s stock, valued at approximately $675,345.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.20% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.